220 related articles for article (PubMed ID: 21442281)
1. Sp1 inhibition-mediated upregulation of VEGF 165 b induced by rh-endostatin enhances antiangiogenic and anticancer effect of rh-endostatin in A549.
Li ZY; Zhu F; Hu JL; Peng G; Chen J; Zhang S; Chen X; Zhang RG; Chen LJ; Liu P; Luo M; Sun ZH; Ren JH; Huang LL; Wu G
Tumour Biol; 2011 Aug; 32(4):677-87. PubMed ID: 21442281
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the effect of rh-endostatin on intratumoral and myocardial micrangium in mice].
Zhang CC; Li K; Wei XY; Chen C; Yuan J; Wang J
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):415-20. PubMed ID: 21875480
[TBL] [Abstract][Full Text] [Related]
3. Effects of recombinant human endostatin and its synergy with cisplatin on circulating endothelial cells and tumor vascular normalization in A549 xenograft murine model.
Li N; Zheng D; Wei X; Jin Z; Zhang C; Li K
J Cancer Res Clin Oncol; 2012 Jul; 138(7):1131-44. PubMed ID: 22402599
[TBL] [Abstract][Full Text] [Related]
4. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors.
Fernando NT; Koch M; Rothrock C; Gollogly LK; D'Amore PA; Ryeom S; Yoon SS
Clin Cancer Res; 2008 Mar; 14(5):1529-39. PubMed ID: 18316578
[TBL] [Abstract][Full Text] [Related]
5. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
von Marschall Z; Scholz A; Cramer T; Schäfer G; Schirner M; Oberg K; Wiedenmann B; Höcker M; Rosewicz S
J Natl Cancer Inst; 2003 Mar; 95(6):437-48. PubMed ID: 12644537
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human endostatin enhances the radioresponse in esophageal squamous cell carcinoma by normalizing tumor vasculature and reducing hypoxia.
Zhu H; Yang X; Ding Y; Liu J; Lu J; Zhan L; Qin Q; Zhang H; Chen X; Yang Y; Yang Y; Liu Z; Yang M; Zhou X; Cheng H; Sun X
Sci Rep; 2015 Sep; 5():14503. PubMed ID: 26412785
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects.
Abdollahi A; Lipson KE; Sckell A; Zieher H; Klenke F; Poerschke D; Roth A; Han X; Krix M; Bischof M; Hahnfeldt P; Grone HJ; Debus J; Hlatky L; Huber PE
Cancer Res; 2003 Dec; 63(24):8890-8. PubMed ID: 14695206
[TBL] [Abstract][Full Text] [Related]
8. Effects of endostatin on expression of vascular endothelial growth factor and its receptors and neovascularization in colonic carcinoma implanted in nude mice.
Jia YH; Dong XS; Wang XS
World J Gastroenterol; 2004 Nov; 10(22):3361-4. PubMed ID: 15484319
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.
Ren Z; Wang Y; Jiang W; Dai W; Jiang Y
PLoS One; 2014; 9(9):e107823. PubMed ID: 25229620
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein.
Wang H; Yang Z; Gu J
Mol Cancer Ther; 2014 Nov; 13(11):2674-87. PubMed ID: 25127900
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs.
Jiang P; Zhang Y; Cui J; Wang X; Li Y
Thorac Cancer; 2022 Jan; 13(2):257-264. PubMed ID: 34855286
[TBL] [Abstract][Full Text] [Related]
13. Discrepancies between antiangiogenic and antitumor effects of recombinant human endostatin.
Huang G; Chen L
Cancer Biother Radiopharm; 2009 Oct; 24(5):589-96. PubMed ID: 19877889
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenesis effects of endostatin in retinal neovascularization.
Bai YJ; Huang LZ; Zhou AY; Zhao M; Yu WZ; Li XX
J Ocul Pharmacol Ther; 2013 Sep; 29(7):619-26. PubMed ID: 23545016
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth.
Zhang K; Wang Y; Yu X; Shi Y; Yao Y; Wei X; Ma X
BMC Cancer; 2017 Dec; 17(1):899. PubMed ID: 29282026
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound-targeted microbubble destruction improved the antiangiogenic effect of Endostar in triple-negative breast carcinoma xenografts.
Jing Y; Xiu-Juan Z; Hong-Jiao C; Zhi-Kui C; Qing-Fu Q; En-Sheng X; Li-Wu L
J Cancer Res Clin Oncol; 2019 May; 145(5):1191-1200. PubMed ID: 30805775
[TBL] [Abstract][Full Text] [Related]
17. The inhibitory effects of rh-endostatin (YH-16) in combination with radiotherapy on lung adenocarcinoma A549 in mice and the underlying mechanisms.
Wu H; Deng J; Yu S; Wang X; Chen Y
J Huazhong Univ Sci Technolog Med Sci; 2010 Feb; 30(1):108-12. PubMed ID: 20155466
[TBL] [Abstract][Full Text] [Related]
18. SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.
Cao ZX; Zheng RL; Lin HJ; Luo SD; Zhou Y; Xu YZ; Zeng XX; Wang Z; Zhou LN; Mao YQ; Yang L; Wei YQ; Yu LT; Yang SY; Zhao YL
Cell Physiol Biochem; 2011; 27(5):565-74. PubMed ID: 21691074
[TBL] [Abstract][Full Text] [Related]
19. Control of angiogenesis by VEGF and endostatin-encapsulated protein microcrystals and inhibition of tumor angiogenesis.
Matsumoto G; Hirohata R; Hayashi K; Sugimoto Y; Kotani E; Shimabukuro J; Hirano T; Nakajima Y; Kawamata S; Mori H
Biomaterials; 2014 Jan; 35(4):1326-33. PubMed ID: 24210874
[TBL] [Abstract][Full Text] [Related]
20. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
